Hwa-ping Feng

747 total citations
38 papers, 573 citations indexed

About

Hwa-ping Feng is a scholar working on Hepatology, Infectious Diseases and Pharmacology. According to data from OpenAlex, Hwa-ping Feng has authored 38 papers receiving a total of 573 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Hepatology, 14 papers in Infectious Diseases and 10 papers in Pharmacology. Recurrent topics in Hwa-ping Feng's work include Hepatitis C virus research (17 papers), HIV/AIDS drug development and treatment (13 papers) and Antibiotics Pharmacokinetics and Efficacy (9 papers). Hwa-ping Feng is often cited by papers focused on Hepatitis C virus research (17 papers), HIV/AIDS drug development and treatment (13 papers) and Antibiotics Pharmacokinetics and Efficacy (9 papers). Hwa-ping Feng collaborates with scholars based in United States, Netherlands and Japan. Hwa-ping Feng's co-authors include Lila M. Gierasch, Joan R. Butterton, Craig W. Vander Kooi, Maurizio Pellecchia, Erik R. P. Zuiderweg, Shawn Y. Stevens, Diana Montgomery, John A. Wagner, Ellen G. J. Hulskotte and Edward O’Mara and has published in prestigious journals such as Hepatology, Biochemistry and Clinical Infectious Diseases.

In The Last Decade

Hwa-ping Feng

38 papers receiving 565 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Hwa-ping Feng United States	11	245	181	163	117	90	38	573
David D. Deininger United States	9	216 0.9×	44 0.2×	107 0.7×	186 1.6×	25 0.3×	14	417
Julio Martín Spain	17	206 0.8×	95 0.5×	281 1.7×	24 0.2×	52 0.6×	47	747
Yeojin Park United States	13	139 0.6×	180 1.0×	207 1.3×	251 2.1×	35 0.4×	22	551
Norman M. Gray United Kingdom	8	230 0.9×	67 0.4×	102 0.6×	219 1.9×	20 0.2×	12	505
Pragyan Acharya India	13	237 1.0×	96 0.5×	136 0.8×	47 0.4×	8 0.1×	19	595
G.C. Viscomi Italy	13	166 0.7×	35 0.2×	82 0.5×	36 0.3×	56 0.6×	23	502
J. J. PLATTNER United States	10	159 0.6×	65 0.4×	73 0.4×	406 3.5×	11 0.1×	25	722
Ping Ruan United States	14	145 0.6×	57 0.3×	177 1.1×	161 1.4×	7 0.1×	25	557
Richa Chandra United States	13	418 1.7×	8 0.0×	140 0.9×	93 0.8×	29 0.3×	26	778
Kiran Dole United States	13	247 1.0×	16 0.1×	106 0.7×	37 0.3×	8 0.1×	22	532

Countries citing papers authored by Hwa-ping Feng

Since Specialization

Citations

This map shows the geographic impact of Hwa-ping Feng's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hwa-ping Feng with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hwa-ping Feng more than expected).

Fields of papers citing papers by Hwa-ping Feng

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hwa-ping Feng. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hwa-ping Feng. The network helps show where Hwa-ping Feng may publish in the future.

Co-authorship network of co-authors of Hwa-ping Feng

This figure shows the co-authorship network connecting the top 25 collaborators of Hwa-ping Feng. A scholar is included among the top collaborators of Hwa-ping Feng based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hwa-ping Feng. Hwa-ping Feng is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Liu, Na, Xiaohong Wang, Jixiang Zhu, et al.. (2023). A single- and multiple-dose study to characterize the pharmacokinetics, safety, and tolerability of ceftolozane/tazobactam in healthy Chinese participants. International Journal of Antimicrobial Agents. 61(3). 106717–106717. 2 indexed citations

Wagenlehner, Flo ri an, Caroline Perry, Thomas M. Hooton, et al.. (2023). P31 Efficacy and safety of oral gepotidacin in the treatment of uncomplicated urinary tract infection: results of two randomized, multicentre Phase 3 trials (EAGLE-2 and EAGLE-3). JAC-Antimicrobial Resistance. 5(Supplement_3). 2 indexed citations

Bajwa, Ednan K., John Palcza, Hwa-ping Feng, et al.. (2022). Effects of an inhaled soluble guanylate cyclase (sGC) stimulator MK-5475 in pulmonary arterial hypertension (PAH). Respiratory Medicine. 206. 107065–107065. 9 indexed citations

Caro, Luzelena, Thomayant Prueksaritanont, Christine Fandozzi, et al.. (2021). Evaluation of Pharmacokinetic Drug Interactions of the Direct-Acting Antiviral Agents Elbasvir and Grazoprevir with Pitavastatin, Rosuvastatin, Pravastatin, and Atorvastatin in Healthy Adults. Clinical Drug Investigation. 41(2). 133–147. 5 indexed citations

Carr, Donna, Zufei Zhang, Qian Si, et al.. (2020). In Vitro Hollow-Fiber Studies Assessing Antibacterial Activity of Ceftolozane/Tazobactam Against Multidrug-Resistant Pseudomonas Aeruginosa. Open Forum Infectious Diseases. 7(11). ofaa469–ofaa469. 3 indexed citations

Huntington, Jennifer A., Brian Yu, Erin Jensen, et al.. (2020). Outcomes in Participants with Renal Impairment from a Phase 3 Clinical Trial for Ceftolozane/Tazobactam Treatment of Nosocomial Pneumonia (ASPECT-NP). Antimicrobial Agents and Chemotherapy. 64(12). 7 indexed citations

Caro, Luzelena, Larissa Wenning, Hwa-ping Feng, et al.. (2019). Pharmacokinetics of elbasvir and grazoprevir in subjects with end-stage renal disease or severe renal impairment. European Journal of Clinical Pharmacology. 75(5). 665–675. 10 indexed citations

Larson, Kajal, et al.. (2018). Population pharmacokinetics of tazobactam/ceftolozane in Japanese patients with complicated urinary tract infection and complicated intra-abdominal infection. Journal of Infection and Chemotherapy. 25(3). 182–191. 11 indexed citations

Feng, Hwa-ping, Luzelena Caro, Christine Fandozzi, et al.. (2018). Pharmacokinetic Interactions Between Elbasvir/Grazoprevir and Immunosuppressant Drugs in Healthy Volunteers. The Journal of Clinical Pharmacology. 58(5). 666–673. 14 indexed citations

10.

Cheung, TT, Joanne Wing Yan Chiu, Man‐Fung Yuen, et al.. (2018). A Phase I, Single- and Multiple-dose Study to Evaluate the Pharmacokinetics of Elbasvir and Grazoprevir in Healthy Chinese Participants. Clinical Therapeutics. 40(5). 719–732.e1. 3 indexed citations

11.

Feng, Hwa-ping, Zifang Guo, Lisa Ross, et al.. (2018). Assessment of drug interaction potential between the HCV direct-acting antiviral agents elbasvir/grazoprevir and the HIV integrase inhibitors raltegravir and dolutegravir. Journal of Antimicrobial Chemotherapy. 74(3). 710–717. 4 indexed citations

12.

Marshall, William L., Hwa-ping Feng, Luzelena Caro, et al.. (2017). No clinically meaningful pharmacokinetic interaction between the hepatitis C virus inhibitors elbasvir and grazoprevir and the oral contraceptives ethinyl estradiol and levonorgestrel. European Journal of Clinical Pharmacology. 73(5). 593–600. 7 indexed citations

13.

Hulskotte, Ellen G. J., R. Douglas Bruce, Hwa-ping Feng, et al.. (2015). Pharmacokinetic interaction between HCV protease inhibitor boceprevir and methadone or buprenorphine in subjects on stable maintenance therapy. European Journal of Clinical Pharmacology. 71(3). 303–311. 13 indexed citations

14.

Khalilieh, Sauzanne, Hwa-ping Feng, Ellen G. J. Hulskotte, Larissa Wenning, & Joan R. Butterton. (2015). Clinical Pharmacology Profile of Boceprevir, a Hepatitis C Virus NS3 Protease Inhibitor: Focus on Drug–Drug Interactions. Clinical Pharmacokinetics. 54(6). 599–614. 6 indexed citations

15.

Feng, Hwa-ping, et al.. (2014). Pharmacokinetic and pharmacodynamic interactions between the hepatitis C virus protease inhibitor, boceprevir, and the oral contraceptive ethinyl estradiol/norethindrone. European Journal of Clinical Pharmacology. 70(9). 1107–1113. 12 indexed citations

16.

Doi, Toshihiko, Kei Muro, Takayuki Yoshino, et al.. (2013). Phase 1 pharmacokinetic study of MK-0646 (dalotuzumab), an anti-insulin-like growth factor-1 receptor monoclonal antibody, in combination with cetuximab and irinotecan in Japanese patients with advanced colorectal cancer. Cancer Chemotherapy and Pharmacology. 72(3). 643–652. 22 indexed citations

17.

Hulskotte, Ellen G. J., Hwa-ping Feng, Fengjuan Xuan, et al.. (2012). Pharmacokinetic Interactions Between the Hepatitis C Virus Protease Inhibitor Boceprevir and Ritonavir-Boosted HIV-1 Protease Inhibitors Atazanavir, Darunavir, and Lopinavir. Clinical Infectious Diseases. 56(5). 718–726. 58 indexed citations

18.

Hulskotte, Ellen G. J., Samir K. Gupta, Fengjuan Xuan, et al.. (2012). Pharmacokinetic interaction between the hepatitis C virus protease inhibitor boceprevir and cyclosporine and tacrolimus in healthy volunteers. Hepatology. 56(5). 1622–1630. 78 indexed citations

19.

Gierasch, Lila M., Erik R. P. Zuiderweg, Maurizio Pellecchia, et al.. (2000). Structural insights into substrate binding by the molecular chaperone DnaK.. Nature Structural Biology. 7(4). 298–303. 164 indexed citations

20.

Feng, Hwa-ping & Lila M. Gierasch. (1998). Molecular chaperones: Clamps for the Clps?. Current Biology. 8(13). R464–R467. 16 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact